ROCKVILLE, Md., Nov. 20,
2023 /PRNewswire/ -- CBMG Holdings (the "Company")
today announced that following the spin-off of the Company's stem
cell business division, it has changed its name to AbelZeta Pharma,
Inc. ("AbelZeta"), which will focus on immune cell business. The
spin-off, approved by the Company's board of directors and
shareholders, allows AbelZeta to focus greater resources on the
development of immune cell therapy for cancer and Inflammation
& Immunology (I&I) diseases.
The name AbelZeta articulates our
confidence in T-cell based therapies to address aggressive cancers
& immune disorders.
"We believe the name AbelZeta best reflects our Company's
culture and values and is the next step in our growth as a
commercially focused immune cell therapeutics company," said Tony
(Bizuo) Liu, Chairman and CEO of the Company. "Abel is an ancient
name long associated with humility, integrity, and conviction, and
the Greek letter ΞΆ, or zeta, is a widely recognized component of
the T-cell receptor in the immune cell research community. The name
AbelZeta articulates our confidence in the T-cell based therapies
to deliver transformative treatments to address aggressive cancers
and serious immune disorders."
The Company currently has 13 ongoing clinical studies in its
immune cell pipeline in the United
States and in China.
About AbelZeta Pharma, Inc.
AbelZeta is a global
clinical-stage biopharmaceutical company with centers of excellence
in Rockville, Maryland and
Shanghai, China. AbelZeta is
focusing on developing innovative and proprietary cell-based
therapeutic products and is committed to ushering in bespoke
treatments that harness the body's own immune system to fight
against hematological malignancies and solid tumors, as well as
inflammatory and immunological diseases. AbelZeta advances research
and development in its own GMP facilities at its centers of
excellence for early-stage clinical studies, with a pipeline
comprised of CAR-T and TIL therapies.
Forward-Looking Statements
Statements in this
communication relating to plans, strategies, specific activities,
and other statements that are not descriptions of historical facts
are forward-looking statements. Forward-looking information is
inherently subject to risks and uncertainties, and actual
results could differ materially from those currently anticipated
due to a number of factors, which include any risks detailed from
time to time in the Company's reports. Such statements are based on
the management's current beliefs and expectations and are subject
to significant risks and uncertainties outside of management and
the Company's control. Given these uncertainties, you should not
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Except as otherwise required by
law, the Company does not undertake any obligation, and expressly
disclaims any obligation, to update, alter or otherwise revise any
forward-looking statements, whether written or oral, that may be
made from time to time, whether as a result of new information,
future events or otherwise.
Company Contact:
Sarah
Kelly
Director of Communications
AbelZeta Pharma, Inc.
Phone: +1 (240) 552 5870
Email: sarah.kelly@abelzeta.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cbmg-holdings-announces-name-change-to-abelzeta-pharma-inc-301993427.html
SOURCE AbelZeta Pharma, Inc.